人乳头瘤病毒预防性疫苗的研究进展及应用前景

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses[J] . Marie-Pierre David,Koen Van Herck,Karin Hardt,Fabian Tibaldi,Gary Dubin,Dominique Descamps,Pierre Van Damme.Gynecologic Oncology . 2009 (3)

Safety of human papillomavirus （HPV）-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials[J] . Dominique Descamps,Karin Hardt,Bart Spiessens,Patricia Izurieta,Thomas Verstraeten,Thomas Breuer,Gary Dubin.Human Vaccines . 2009 (5)

A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China[J] . You-lin Qiao,John W Sellors,Paul S Eder,Yan-ping Bao,Jeanette M Lim,Fang-hui Zhao,Bernhard Weigl,Wen-hua Zhang,Roger B Peck,Ling Li,Feng Chen,Qing-jing Pan,Attila T Lorincz.Lancet Oncology . 2008 (10)

Impact of vaccination with Cervarix? on subsequent HPV-16/18 infection and cervical disease in women 15–25 years of age[J] . Diane M. Harper.Gynecologic Oncology . 2008 (3)

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial[J] . Jorma Paavonen,David Jenkins,F Xavier Bosch,Paulo Naud,Jorge Salmerón,Cosette M Wheeler,Song-Nan Chow,Dan L Apter,Henry C Kitchener,Xavier Castellsague,Newton S de Carvalho,S Rachel Skinner,Diane M Harper,James A Hedrick,Unnop Jaisamrarn,Genara AM Limson,Marc Dion

Efficacy of a quadrivalent prophylactic human papillomavirus （types 6, 11, 16, and 18） L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials[J] . Elmar A Joura,Sepp Leodolter,Mauricio Hernandez-Avila,Cosette M Wheeler,Gonzalo Perez,Laura A Koutsky,Suzanne M Garland,Diane M Harper,Grace WK Tang,Daron G Ferris,Marc Steben,Ronald W Jones,Janine Bryan,Frank J Taddeo,Oliver M Bautista,Mark T Esser,Heather L Sings,Micki Ne

Stress, Age, and Immune Function: Toward a Lifespan Approach[J] . Jennifer E. Graham,Lisa M. Christian,Janice K. Kiecolt-Glaser.Journal of Behavioral Medicine . 2006 (4)

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial[J] . Diane M Harper,Eduardo L Franco,Cosette M Wheeler,Anna-Barbara Moscicki,Barbara Romanowski,Cecilia M Roteli-Martins,David Jenkins,Anne Schuind,Sue Ann Costa Clemens,Gary Dubin.The Lancet . 2006 (9518)

Chapter 6: Epidemiology and transmission dynamics of genital HPV infection[J] . Ann N. Burchell,Rachel L. Winer,Silvia de Sanjosé,Eduardo L. Franco.Vaccine . 2006

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses[J] . Marie-Pierre David,Koen Van Herck,Karin Hardt,Fabian Tibaldi,Gary Dubin,Dominique Descamps,Pierre Van Damme.Gynecologic Oncology . 2009 (3)

Safety of human papillomavirus （HPV）-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials[J] . Dominique Descamps,Karin Hardt,Bart Spiessens,Patricia Izurieta,Thomas Verstraeten,Thomas Breuer,Gary Dubin.Human Vaccines . 2009 (5)

A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China[J] . You-lin Qiao,John W Sellors,Paul S Eder,Yan-ping Bao,Jeanette M Lim,Fang-hui Zhao,Bernhard Weigl,Wen-hua Zhang,Roger B Peck,Ling Li,Feng Chen,Qing-jing Pan,Attila T Lorincz.Lancet Oncology . 2008 (10)

Impact of vaccination with Cervarix? on subsequent HPV-16/18 infection and cervical disease in women 15–25 years of age[J] . Diane M. Harper.Gynecologic Oncology . 2008 (3)

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial[J] . Jorma Paavonen,David Jenkins,F Xavier Bosch,Paulo Naud,Jorge Salmerón,Cosette M Wheeler,Song-Nan Chow,Dan L Apter,Henry C Kitchener,Xavier Castellsague,Newton S de Carvalho,S Rachel Skinner,Diane M Harper,James A Hedrick,Unnop Jaisamrarn,Genara AM Limson,Marc Dion

Efficacy of a quadrivalent prophylactic human papillomavirus （types 6, 11, 16, and 18） L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials[J] . Elmar A Joura,Sepp Leodolter,Mauricio Hernandez-Avila,Cosette M Wheeler,Gonzalo Perez,Laura A Koutsky,Suzanne M Garland,Diane M Harper,Grace WK Tang,Daron G Ferris,Marc Steben,Ronald W Jones,Janine Bryan,Frank J Taddeo,Oliver M Bautista,Mark T Esser,Heather L Sings,Micki Ne

Stress, Age, and Immune Function: Toward a Lifespan Approach[J] . Jennifer E. Graham,Lisa M. Christian,Janice K. Kiecolt-Glaser.Journal of Behavioral Medicine . 2006 (4)

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial[J] . Diane M Harper,Eduardo L Franco,Cosette M Wheeler,Anna-Barbara Moscicki,Barbara Romanowski,Cecilia M Roteli-Martins,David Jenkins,Anne Schuind,Sue Ann Costa Clemens,Gary Dubin.The Lancet . 2006 (9518)

Chapter 6: Epidemiology and transmission dynamics of genital HPV infection[J] . Ann N. Burchell,Rachel L. Winer,Silvia de Sanjosé,Eduardo L. Franco.Vaccine . 2006